. Illustrating the intersection between development and malignancy are the direct roles played by core developmental pathways (Wnt, sonic hedgehog protein (Shh), bone morphogenetic protein (BMP) and neurogenic locus notch homologue protein (Notch)) 3 in tumorigenesis, the influence of many generic drivers of malignancy (cellular tumour antigen p53 (P53; also known as TP53), phosphate and tensin homologue (PTEN) and p16) [4] [5] [6] on development and the fact that many key developmental genes are frequently mutated in cancer as well (EGFR, NOTCH and SHH) 7, 8 . Emerging from these observations is a molecular and functional interdependence between classic drivers of cancer and developmental pathways that engender malignancy. Using the interface between development and malignancy as our guide, this Review describes the cellular and molecular mechanisms that oversee the development of CNS glia and identifies the unifying characteristics between normal glial development and the generation of their malignant counterparts in glioma.
A developmental framework for glioma There are two broad categories of CNS glia: oligodendrocytes and astrocytes. Oligodendrocytes form the myelin sheath that surrounds axons and is essential for saltatory nerve conduction 9 . Astrocytes occupy a variety of roles essential for homeostatic CNS function, including formation of the blood-brain barrier, buffering neurotransmitter levels, formation of synapses and providing metabolic support to neurons 10 . Accordingly, the brain offers an extraordinary degree of lineage complexity and a broad spectrum of associated malignancies. Among forms of brain cancer, diffuse gliomas are the most frequent and have the worst prognosis. Diffuse gliomas comprise three categories: astrocytoma, oligodendroglioma and glioblastoma (GBM) 11 ( Fig. 1) . As suggested by the respective names of the glioma subtypes, oligodendroglioma and astrocytoma, these tumours share common features of their normal counterparts, including histological, functional and molecular characteristics. Furthermore, astrocytomas can also recur after primary intervention as secondary GBM. Diagnosis of diffuse glioma has integrated classic histological analysis and newly identified genetic criteria, with isocitrate dehydrogenase (iDH) status and co-deletion of 1p/19q serving as key genetic landmarks 11 . Among diffuse glioma (herein glioma), GBM is the most frequent and has the worst prognosis. Accordingly, GBM has been the subject of intense scrutiny over the years, with recent profiling efforts identifying five molecular subgroups of GBM 12, 13 . Despite common histopathological features, paedia tric high-grade glioma (pHGG) is considered distinct from its adult counterpart as it is associated with unique anatomical locations, responses to radiotherapy and clinical outcomes 14 . Moreover, pHGG has considerably fewer somatic mutations than adult gliomas, with hallmark mutations occurring in histone H3.3 that infer an epigenetic origin of disease 15, 16 ( Fig. 1) . Finally, pHGG occurs in the developing brain, further distinguishing it from adult glioma, suggesting that it exploits active proliferative and migratory programmes in this neuro developmental context. Despite these advances in both adult and paediatric glioma, survival has not substantially changed in over 70 years, highlighting the need for new interventions, driven by a deeper understanding of the underlying biology of this malicious disease.
Over the past decade, advances in genomics have delivered critical insights that have shaped the cataloguing of tumour subtypes, whereas the discovery of the glioma stem cell (GSC) has guided functional studies on the origins and recurrent nature of this disease 17 . Although the GSC sits at the apex of the cellular hierarchy, how it produces the vast cellular constituency associated with frank glioma tumori genesis remains very poorly defined. Given that the vast majority of cells comprising malignant glioma are glial in nature, one way of deciphering how these tumour cells are produced is to understand how glial developmental processes are utilized during tumorigenesis. Thus, the central hypothesis that we explore in this Review is that if we can understand how to make glial cells, then we can better understand glioma tumorigenesis.
Importantly, although there are clear parallels between brain development and glioma tumorigenesis, much of what we know about the molecular and cellular mechanisms underlying developmental gliogenesis has been discerned from the spinal cord. The spinal cord is often chosen for studies of CNS development because its relatively simple anatomy and accessibility make it a tractable system in which to conduct complex molecular studies. Moreover, all the major neurogenic transcription factors and signalling pathways have been shown to play similar roles in both the spinal cord and the developing cortex. These observations indicate that there is a strong conservation of gene and pathway function across these CNS regions and provide a rationale for exploring gliogenic mechanisms that control spinal cord development as a developmental canvas upon which we can understand glioma tumorigenesis.
Neural stem cell-glial progenitor axis The gliogenic switch. Given the intimate association between glioma and glial cells, developmental gliogenesis serves as a natural starting point for building a developmental framework for glioma. If the GSC sits at the apex of the tumour hierarchy and is responsible for the generation of glioma cells that populate the bulk tumour, the analogous relationship in development is the neural stem cell (NSC)-glial progenitor axis. Given this, we begin with an overview of early gliogenesis, focusing on the gliogenic switch.
Mammalian gliogenesis consists of three separate processes that ensure that the progenitor pool produces the proper number of glia. First, the processes that promote neurogenesis must be inhibited to allow for gliogenesis. Second, the progenitor pool must also be maintained so as to protect against depletion. Finally, progenitor populations must produce a set number of glial cells. This developmental interval has been termed the 'gliogenic switch' and is used across diverse CNS regions and model organisms to initiate gliogenesis.
Much of what we know about the gliogenic switch comes from studies in the developing mouse spinal cord, . b | Comparison of 5 year progression-free survival for different tumour subtypes, which represents the percentage of people whose glioma has not worsened 5 years after treatment. Data are derived from the following sources: the American Cancer Society , the National Brain Tumour Society and ReF. 101 . Anaplastic astrocytoma (AA) and GBM have significantly worse outcomes than the 'All brain tumours' and 'Oligo' (diffuse and anaplastic oligodendroglioma) groups. c | Common genetic criteria for glioma subtypes are listed. Gliomas are diagnosed by histopathology and genetic features and named accordingly. For example, a glioma subtype would be represented as 'oligodendroglioma, IDH mutant and 1p/19q co-deletion' . Genetic criteria used to classify glioma subtypes were derived from ReF.
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. Recently , the WHO has reclassified glioma subtypes on the basis of a set of defining genetic mutations. These defining mutations are shown in part c. Although paediatric high-grade glioma (pHGG) is histologically indistinguishable from adult GBM, it is considered distinct from adult GBM because the spectrum of driver mutations is considerably different 14, 15 . GCIMP, glioma-CpG island methylator phenotype.
where the timing of this transition is clearly defined: neurogenesis ceases at embryonic day (E) 11.5 and glio genesis commences at E12.5 (Fig. 2) . Using the pMN domain in the spinal cord as a model system, deletion and fate mapping studies have shown that progenitor populations during gliogenic stages are generated after neuro genesis, suggesting that neurons and glia are generated from distinct progenitors 18, 19 . This concept was reinforced by studies in zebrafish demonstrating that gliogenic progenitors are recruited to the pMN domain after neurogenesis 20 . Moreover, heterochronic transplantation studies in the developing CNS with freshly isolated neurogenic and glio genic populations demonstrate stark phenotypic differences between these embryonic populations: neurogenic populations are multipotent whereas gliogenic popu lations are not 21 . Together, these studies suggest that the cellular substrates giving rise to neurons and glia have unique properties and may also have distinct origins.
These cellular observations correspond with molecular changes that play vital roles in determining the initiation of glial fate during the gliogenic switch. Among these molecular changes, the induction of the transcription factors SOX9 and nuclear factor I/A (NFIA) play essential roles during the initiation of gliogenesis. SOX9 is induced in progenitor populations around E10.5, and SOX9 deletion results in a delay in the onset of gliogenesis and concordant extension of the neurogenic phase 22 . NFIA is induced at E11.5 in the spinal cord, and studies in the embryonic chick spinal cord revealed that NFIA is necessary and suffi cient for gliogenesis 23 . Additional studies have shown that SOX9 and brain-specific homeobox/POU domain protein 2 (BRN2; also known as POU3F2) directly regulate NFIA induction and that SOX9 and NFIA collaborate to drive expre ssion of early glial genes 24, 25 . From these studies, a transcriptional regulatory cascade emerges in which SOX9 and BRN2 directly regulate NFIA induction and subsequently form protein partnerships to further promote glial differentiation.
Among the central developmental pathways, NOTCH signalling plays an essential role during the gliogenic switch. Deletion of NOTCH effectors, transcription factors HES1 and HES5, results in precocious neuronal differentiation and a complete loss of glia 26 . Complementary increases in NOTCH signalling produce more glia, suggesting that NOTCH signalling is instructive 27 . However, studies in zebrafish and chick have shown that although enhanced NOTCH activity produces more glia, these cells are not generated at earlier timepoints, suggesting that NOTCH facilitates the gliogenic switch by maintaining the progenitor pool 23, 27 
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• self-renewing and are present during neurogenesis around embryonic day (E) 9.5 to E11. The gliogenic switch occurs around E12.5, when NSCs are gradually replaced by glial progenitor cell (GPC) populations, astrocyte precursors (APCs) and oligodendrocyte precursors (OPCs). Neurogenic locus notch homologue protein (NOTCH) functions throughout the gliogenic switch interval to maintain the glial progenitor pool, whereas POU domain, class 3, transcription factor 2 (BRN2) and transcription factor SOX9 collaborate to drive nuclear factor I/A (NFIA) induction. It is important to note that APCs and OPCs are generated in distinct progenitor domains within the developing brain, and, accordingly , spatial patterning mechanisms also contribute to specifying their identities. b | There are a number of molecular and functional properties that are conserved between GPC and glioma stem cell (GSC) populations. These parallels suggest that the GSC behaves similarly to glial precursor populations. HES, transcription factor HES; Olig2, oligodendrocyte transcription factor 2.
The gliogenic switch and glioma. Applying the cell biology underlying the gliogenic switch to glioma remains challenging because of the clear operational differences between NSCs and GSCs regarding their in vivo neurogenic capacity: NSCs have it and GSCs do not (Fig. 2) . Thus, it is unlikely that a bona fide NSC exists within a tumour. Instead, the existing GSCs likely resemble the glial precursor populations present after the gliogenic switch. In support of this notion, recent profiling studies identified SOX2, BRN2 and oligodendrocyte transcription factor 2 (Olig2) as part of a transcriptional node present in GSCs 30 . Moreover, NFIA expression in glioma is tightly correlated with BRN2, providing additional molecular evidence that GSCs may be endowed with glial precursor properties 25 . In addition, adult NSCs in the subventricular and subgranular zones express several glial markers, further supporting the glial nature of these populations. Nevertheless, it is possible that genetic mutation, coupled with selective pressures, produces a GSC population that has co-opted both NSC and glial identities. Alternatively, it is possible that the bulk GSC population is composed of multiple subpopulations with these distinct glial-like and NSC-like properties. Indeed, recent clonal mapping of GSCs identified discrete clones that are resistant to chemotherapy, suggesting that functional heterogeneity exists within this population 31 . Because glioma tumours exhibit features consistent with glial precursor populations, a natural question that emerges is whether the developmental determinants of glial cell fate also contribute to tumorigenesis. Towards this, several recent studies on NFIA and SOX9 have highlighted the critical role that these factors play in glioma tumorigenesis. NFIA is highly expressed in all grades of astrocytoma and GBM, whereas functional studies in human and mouse glioma cell lines have shown that NFIA regulates glioma tumorigenesis via direct transcriptional repression of p21 (ReFS [32] [33] [34] ). Although these studies reveal a general role in glioma proliferation in xenograft models, studies in native mouse models reveal that overexpression of NFIA can convert an oligo dendroglioma subtype into an astrocytoma 34 . This observation suggests that manipulating glial fate determinants can alter tumour 'identity' and points to the possibility of differentiation therapy for glioma via these developmental mechanisms (Fig. 3) .
Although SOX9 is also highly expressed in glioma, its role is not as clearly defined 35 . Studies in glioma cell lines have shown that SOX9 promotes proliferation and tumorigenesis in xenografts, but the underlying mechanisms remain poorly defined 36 . Studies in another form of brain cancer, medulloblastoma, have shown that SOX9 is linked to n-myc proto-oncogene protein (also known as MYCN) and SHH signalling, suggesting that parallel mechanisms also apply to glioma 37 . Additional evidence of a role for SOX9 in glioma comes from recent studies showing that deletion of SOX9-regulated and BRN2-regulated enhancers in the NFIA locus not only inhibits NFIA expression but also inhibits tumorigenesis in a native mouse model of glioma 25 . Although these observations do not directly demonstrate a function for SOX9 and BRN2 in glioma tumorigenesis, they strongly suggest that the regulatory relationships overseeing the gliogenic switch are present in glioma and directly contribute to tumorigenesis.
Given its central role in progenitor maintenance in the CNS, the role of the Notch pathway in glioma tumorigenesis and the expression of pathway components have been extensively investigated 38 . Functional studies have been performed predominately in GSC models, in which NOTCH has been shown to promote both in vitro growth and tumorigenesis in xenografts. Several clinical trials have utilized approaches geared towards inhibiting NOTCH activity in glioma, albeit with limited success, partly owing to the inherit complexity of the pathway and the context-specific functions of NOTCH signalling 38 . For example, knockdown of recombining binding protein suppressor of hairless (RBPJ), a key effector of NOTCH signalling, in human GSC models inhibited tumorigenesis, whereas deletion of RBPJ in a platelet-derived growth factor (PDGF)-driven native mouse model accelerated tumour growth 39, 40 . These seemingly disparate findings highlight the importance of cellular and genetic context when manipulating NOTCH signalling. Moreover, recent profiling studies using receptor tyrosine kinase (RTK) inhibitor-resistant GSC populations identified a NOTCH-activated b | Functional studies in endogenously generated mouse models of oligodendroglioma indicate that overexpression of NFIA can convert an oligodendroglioma into an astrocytoma 25 . These observations are consistent with the developmental role of NFIA in promoting the astrocyte fate at the expense of the oligodendrocyte fate and suggest that manipulating glial fate determinants influences the subtype or identity of the glioma. In the future, it will be important to test this hypothesis with other transcriptional and signalling determinants of glial fate as this approach may be harnessed for differentiation therapy. A number of candidate transcription factors that are thought to have crucial roles in glial development and are implicated in glioma tumorigenesis are shown; however, their role has not been definitively demonstrated (indicated by question marks). Olig2, oligodendrocyte transcription factor 2; PDGF, platelet-derived growth factor ; SOX9, transcription factor SOX9; STAT3, signal transducer and activator of transcription 3. developmental programme that promotes expression of key gliogenic genes, including OLIG2, NFIA and multiple SOX genes 41 . These findings further illustrate the importance of cellular and environmental context when examining NOTCH function and reinforce the links between prospective GSC populations and the transcriptional mechanisms regulating the gliogenic switch. Finally, we must also consider the possibility that NOTCH may not be essential for glioma tumorigenesis, making it a flawed target, or that current pharmacological inhibitors are not effective or are nonspecific in the context of glioma.
Oligodendrocytes: a nexus for glioma? After NSCs initiate gliogenesis via the gliogenic switch, the resultant glial precursors subsequently differentiate into the two glial sublineages: oligodendrocytes and astrocytes. The generation of each glial sublineage is the result of a series of differentiative steps, culminating in the production of a physiologically mature cell 6, 42 . Importantly, each of these steps is governed by a distinct set of transcription factors and signalling pathways, some of which are also implicated in glioma tumorigenesis.
Oligodendrocyte lineage development. Among cells of the CNS, the oligodendrocyte lineage is one of the best characterized, both in terms of the lineage's progressive differentiation and markers for the specific stages of lineage progression 43, 44 . Because of this progressive nature of differentiation, oligodendrocytes can be used as a paradigm for better understanding lineage dysregulation during malignant glioma.
During their development, oligodendrocytes progress from specified oligodendrocyte precursor cells (OPCs) that occupy discrete germinal centres (pMN in spinal cord and medial and lateral ganglionic eminences in cortex) to migratory premyelinating oligodendrocytes and finally to mature myelinating oligodendrocytes (Fig. 4) . This course of differentiation begins around E13.5, with myelination commencing during early perinatal stages and continuing throughout postnatal development. During this differentiation process, OPCs exit the cell cycle, begin expressing genes required for myelination and undergo a number of morphological changes important for their physiological role in axon ensheathment. However, not all OPC populations differentiate into myelin-producing oligodendrocytes. This is in stark contrast to neuronal and astrocyte precursor populations, which do not reside in the adult CNS; resident OPC populations are maintained in the adult CNS and retain their proliferative, migratory and differentiative potential 45 . These properties of OPCs in the adult have important implications for the origins of glioma (see below).
These resident OPC populations express neuronglial antigen 2 (NG2), have been termed 'NG2 cells' and are often considered a separate class of glial cell (Fig. 4) . Despite their fairly uniform distribution across the brain, NG2 cells exhibit diverse developmental potentials, and NG2 populations in white matter are more prone to generate myelin than those in grey matter 46 .
Interestingly, subsets of NG2 cells have the potential to generate astrocytes during late development, but this capacity is lost in postnatal stages, suggesting plasticity in their cellular potentials during development 47 . Moreover, subsets of NG2 cells have varying developmental potential towards myelination and astrocyte production, which suggests a hidden reservoir of diverse NG2 subpopulations that remain to be defined 48 . The molecules that distinguish the phases of oligodendrocyte lineage development and the transcription factors that oversee this process are well described 43, 44 .
Another key transcription factor that operates in OPCs is SOX10, which is exclusively expressed in the oligodendrocyte lineage and is induced by Olig2 in OPCs at the onset of gliogenesis 51 . SOX10 appears to play multiple roles in oligodendrocyte development as it regulates PDGF receptor-α (PDGFRα) expression in OPCs and induces expression of myelin genes later in lineage development 51, 52 . These key roles are supported by genetic studies in mice demonstrating that SOX10 is required for OPC differentiation. In addition to their roles in promoting OPC development, another facet of Olig2 and SOX10 function is the suppression of astrocyte development. In Olig2-mutant and Sox10-mutant mice, erstwhile OPC populations are converted into astrocytes 25, 50 . Mechanistically, Olig2 and SOX10 function to antagonize the ability of NFIA and SOX9 to activate key astrocyte genes 25 . This antagonism is reciprocal and highlights the dual roles of these transcription factors in determining fates of glial sublineages.
A host of signalling pathways are implicated in promoting the different phases of oligodendrocyte lineage development. PDGFRα, an RTK that is expressed in OPCs and is rapidly downregulated during terminal differentiation, is one signalling pathway that plays a role in glioma 53, 54 . Consistent with its expression dynamics, PDGFRα promotes the proliferation and survival of OPCs, with its downregulation serving as a temporal cue that triggers differentiation. Indeed, in vitro and in vivo studies have shown that loss of PDGFRα results in precocious differentiation of oligodendrocytes and an overall reduction in their number 53, 54 . Consistent with this, inhibition of downstream RTK pathway components mitogen-activated protein kinase (MAPK)-extracellular-signal-regulated kinase (ERK) impairs the ability of PDGFRα to suppress OPC differentiation 55 , reinforcing the notion that mitogenic pathways generally suppress differentiation of progenitor populations and thus engender a permissive state for malignant transformation. Oligodendrocytes: an origin of glioma? Identifying the cellular substrates that incur driver mutations in key tumour suppressor or oncogene pathways and subsequently give rise to glioma is a major question in the field of glioma biology. This 'cell of origin' has been viewed by some as the key to understanding disease pathogenesis. Pioneering work in native mouse models using RCAS (replication-competent avian sarcoma-leukosis virus long terminal repeat with splice acceptor)/tumour virus A (TVA)-based targeting of resident astrocytes or NSCs with oncogenes revealed that resident NSCs in the brain provide a much more permissive environment for glioma tumorigenesis 56 . These findings have also been demonstrated in genetic models that utilize deletion of key tumour suppressors in mice 57, 58 . From these studies, two key features of prospective cells of origin emerged: enhanced proliferative and migratory potential. Given that OPCs are the most proliferative and migratory cell population that resides in the adult brain and have been estimated to comprise ~10% of the cellular constituency of the adult brain, they possess both the properties of a cell of origin and sufficient cell numbers to provide opportunity for malignant transformation 47 . Indeed, a series of recent papers have pointed to the OPC as serving as a potential cell of origin in mouse models of glioma. One study took advantage of mosaic analysis with double markers (MADM) to analyse clones exhibiting loss of heterozygosity in tumour suppressor genes NF1 and P53, finding that OPCs make up the majority of proliferative cells within malignant glioma and could serve as the cell of origin 59 . Similarly, targeted deletion of these key tumour suppressors in OPC populations (via the OPC-specific Cre, NG2-Cre) supported malignant glioma tumorigenesis in genetic models 60 . Further supporting this notion are transplantation data showing that NG2 cells derived from both mouse models and primary human tumours can support glioma tumorigenesis 61, 62 . This experimental evidence, coupled with their normal biological properties, suggests that the origins of malignant glioma dwell within resident OPCs in the adult brain.
The potential OPC origin of glioma implicates their molecular determinants in glioma tumorigenesis. Over the past decade, several studies have begun deciphering the role of Olig2 in glioma tumorigenesis. Olig2 is expressed in all forms of glioma and is also highly expressed in GSC populations extracted from primary tumours 63, 64 . In NSC models of glioma that are driven by loss of Ink4a/Arf require Olig2 expression for tumorigenesis and this function of Olig2 is mediated in part through suppression of p21 (ReF. 63 ). Moreover, the effects of Olig2 are P53-dependent, in which it functions by regulating P53 acetylation, thereby suppressing its capacity to bind DNA and activate transcription 65 . Recently, in native mouse models of glioma, Olig2 has been shown to function through modulation of epidermal growth factor receptor (EGFR) signalling, with the loss of Olig2 slowing tumour progression and shifting the type of GBM from proneural to classical 66 (see Fig. 1 ). This observation provides additional evidence that key regulators of gliogenesis can alter glioma identity (similar to NFIA, see earlier discussion). Interestingly, studies have shown that phosphorylation regulates the function of Olig2 in glioma, suggesting that pharmacologically targeting this post-translational event is an avenue for future glioma therapeutics 67 . Similar to its SOX-E family counterpart SOX9, the role of SOX10 in glioma formation remains poorly defined. Despite being an oligodendrocyte-specific marker, SOX10 demonstrates widespread expression across the full spectrum of glioma subtypes 68 . However, functional studies in an RCAS-TVA glioma model driven by PDGFRβ show that overexpression of SOX10 mildly promotes tumorigenesis 68 . As SOX10 collaborates with Olig2 to suppress the generation of astrocytes, it is possible that manipulating its expression may similarly influence glioma identity.
PDGF signalling has long been implicated in many aspects of tumour biology 69 , which, coupled with its essential role in OPC proliferation, makes it an area of intense investigation in glioma. Genomic studies revealed that 11% of GBMs have amplification of PDGFRα, whereas expression studies in tumours revealed that it demonstrates heterogeneous expression in all grades of glioma 70, 71 . Moreover, several types of mutation variants in the PDGFRα locus have been identified to cause increased receptor tyrosine kinase activity. Together, these observations implicate PDGFRα signalling as a key driver of glioma tumorigenesis. Consistent with these features, several studies have shown that manipulation of PDGFRα in mouse glioma models promotes the formation of oligodendroglioma and that complementing loss of p16-ARF can trigger formation of higher-grade oligodendroglioma and malignant glioma 72 . That manipulation of PDGFRα predominately supports the generation of oligodendroglioma is consistent with its role in OPC development. However, that genetic loss of tumour suppressors can alter the type of tumour generated suggests that the interplay between development and mutation also influences the differentiative state of a given tumour. Finally, PDGFRα functions as an RTK, and because RTKs are drivers of several forms of cancer, numerous pharmacological inhibitors have been developed that inhibit their activity. Several of these RTK inhibitors have been tested in clinical trials for malignant glioma and none have effectively affected survival 73 , highlighting both the complexity of this disease and the dire need for new targeting strategies.
Astrogenesis and glioma heterogeneity
Unlike their cellular counterparts in the CNS, the generation of astrocytes has remained poorly defined at both the cellular and molecular levels. There are several reasons for this: the paucity of reliable markers, the difficulty in modelling their complex array of diverse functions and a general apathy in the neuroscience community towards this critical topic. Nevertheless, a series of recent papers have begun to unravel the seemingly enigmatic biology surrounding the generation of the most abundant cell type in the CNS.
Astrocyte lineage development. Identifying markers that distinguish astrocytes and specifically those that define the phases of lineage progression is essential to improving our understanding of astrocyte development. GFAP has long been heralded as the prototypical marker, although it is expressed in a minority of astrocytes and is induced at the terminal stages of their differentiation 10 . Therefore, major efforts have been made to identify more reliable astrocyte markers, to date the most useful of which is cytosolic 10-formyltetrahydrofolate (ALDH1L1) 74 . In terms of stage-specific progression, in the spinal cord it is known that NFIA, SOX9 and sodium-dependent glutamate/aspartate transporter (GLAST1; also known as SLC1A3) are induced at E12.5, whereas GFAP is induced around E18.5 (Fig. 4) . Whether other genes are specifically induced during these intermediate stages of development remains poorly defined. Recently, two studies sought to define the molecular profiles of these intermediate stages, both finding that astrocytes, similar to their neuronal and oligodendrocyte counterparts, demonstrate progressive changes in gene expression during lineage development 75, 76 . Among the genes induced during these intermediate stages of astrocyte lineage progression are APC-stimulated guanine nucleotide exchange factor 1 (Asef1; also known as ARHGEF4) and nuclear factor, erythroid derived 2, like 1 (NFE2L1), both of which demonstrate astrocyterestricted expression. Although defining these stages at the molecular level is essential, so is understanding the functional properties of intermediate astrocyte precursor populations. Recent studies in both the spinal cord and the cortex have shown that astrocyte precursor populations retain proliferative properties, with the serine/ threonine-protein kinase Braf (BRAF) playing a key role in the proliferation of astrocyte precursors in this developmental context 77, 78 (Fig. 4) . Interestingly, mutations in BRAF have been associated with low-grade astrocytoma 79 , suggesting a developmental basis for its function in malignancy. Nevertheless, in both instances, precursor populations that have migrated out of the germinal zones continue to proliferate and divide during restricted developmental windows, with these 'pioneering astrocytes' comprising as much as ~50% of resident cortical astrocytes in the adult. Importantly, unlike OPCs, these proliferative events occur only during development and are not retained in resident astrocytes under homeostatic conditions. Clearly, astrocyte precursor populations exist across a spectrum of developmental states, with retention of proliferative capacity during perinatal stages being a recently identified property. Another facet of astrocyte development that has recently garnered a lot of attention is their cellular diversity. Given that astrocytes execute a wide range of diverse functions, it stands to reason that they may also exhibit extensive cellular heterogeneity. Studies in the developing spinal cord have shown that dorsal-ventral patterning mechanisms controlling neuronal subtype diversification also oversee the generation of distinct astrocyte subpopulations 80, 81 . Application of these principles to the developing and adult brain is confounded by a lack of patterning-associated mouse tools; however, a series of recent studies have begun to dissect astrocyte heterogeneity in the adult brain. Using comparative expression profiling across distinct brain regions, two recent studies have shown that astrocytes from different brain regions are endowed with distinct molecular and functional properties 82, 83 . In addition,
another study identified five distinct astrocyte subpopulations that are present across five adult brain regions 84 . Interestingly, these populations are present in the developing cortex and are endowed with unique proliferative and migratory properties, suggesting a link to the pioneering astrocyte phenomenon. Together, these studies reveal the potentially vast reservoir of diverse astrocyte populations that reside in the brain.
At the molecular level, much of what we know about astrocyte development is based on studies linked to the gliogenic switch and the regulation of GFAP expression. Several studies have shown that NFIA and SOX9, key regulators of the gliogenic switch, also regulate GFAP expression 22, 23 . These roles appear to be separate from the gliogenic switch, as expression of both SOX9 and NFIA is retained in mature astrocytes and is associated with key signalling pathways linked to GFAP induction in both the spinal cord and the brain 22, 23, 85, 86 . Among these key pathways is ciliary neurotrophic factor (CNTF)-membrane glycoprotein 130 (gp130; also known as IL6ST)-signal transducer and activator of transcription (STAT) signalling, which plays a central role in the differentiation of astrocytes 87, 88 . Mechanistically, STAT3 cooperates with NFIA to drive GFAP expression in a NOTCH-dependent manner 29 . Thus, NOTCH signalling also appears to play a myriad of roles during gliogenesis. Additional evidence for this comes from studies showing that SOX9 expression in astrocytes requires NOTCH signalling 28 . Moreover, the knockdown of SOX9 in NOTCH1-activated NSCs impaired the generation of astrocytes, suggesting that the role of NOTCH in astrocyte development is dependent on its promotion of SOX9 (ReF.
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). Moving forward, it will be important to delineate the mechanisms that uncouple the functions of these key factors in the gliogenic switch from their roles in astrocyte differentiation. Towards this, recent studies have shown that the transcription factor zincfinger and BTB domain-containing protein 20 (ZBTB20) promotes astrocyte development and cooperates with NFIA and SOX9 but does not directly regulate GFAP expression, suggesting that ZBTB20 functions during these intermediate phases of development 90 .
Astrocytes and heterogeneity in glioma. One cardinal feature of glioma is the immense cellular diversity of the bulk tumour, which is largely composed of pathological analogues of the normal tissue. Given the abundance of astrocytes in the adult brain, coupled with the astro-glial-like histopathological features of malignant glioma, it is likely that astrocytes and their derivatives make up a considerable portion of this heterogeneous cellular constituency.
Given these links, a question that emerges is whether astrocytes can also serve as a cell of origin for GBM or astrocytoma. Several studies have targeted astrocytes using GFAP-associated tools in mouse models (RCAS-TVA and conditional mouse genetics) and found that manipulating drivers in resident astrocytes in the adult brain does not result in highly penetrant glioma tumorigenesis 56, 57 . The likely reason for the low penetrance in targeted astrocytes is that they are postmitotic and transformation events that occur within them would have to trigger a series of de-differentiation events to generate the cellular constituency of glioma. On the basis of these studies, it would seem that triggering these de-differentiation events in astrocytes is a fairly rare occurrence. However, these studies rely on GFAP expression for gene manipulation and thus likely do not comprehensively target all astrocytes. Thus, it is possible that some astrocytes are more prone to malignant transformation or triggering de-differentiation than others. Examples for this phenomenon come from other pathological states in the CNS, in which recent studies have shown that after brain injury subsets of astrocytes can convert into neurons 91 . Given that these select astrocyte populations are endowed with latent neurogenic capacity, it is possible that these same populations may also be more susceptible to de-differentiation and subsequent malignant transformation. Together, these observations further highlight the need to generate additional mouse tools for selective targeting of astrocyte populations in the adult brain.
These observations raise the question of whether we can use the presence of diverse astrocyte subpopulations in the brain to explain the cellular heterogeneity of malignant glioma. Regional diversity is one major consideration, as glioma can emerge across numerous brain regions and, accordingly, tumours derived from these regions may exhibit the molecular features of these region-specific astrocytes. Another consideration is local diversity in the form of astrocyte subpopulations within specific brain regions. The same study that identified five astrocyte subpopulations in the adult brain went on to show that four of these populations are present in primary human glioma and multiple mouse models of glioma 84 . At the molecular level, these glioma subpopulations share analogous gene expression signatures with their astrocyte counterparts, suggesting that cellular heterogeneity present within glioma is partially derived from these astrocyte subpopulations. Finally, given that glioma also comprises cells exhibiting undifferentiated histopathological features, it is likely that part of this cellular heterogeneity is derived from intermediate precursor populations that reside along the course of the astrocyte lineage trajectory 77, 78 . Another method for discriminating cellular diversity is single-cell RNA sequencing. Several studies have used this approach for GBM, finding diverse gene expression profiles that infer the presence of diverse cell populations that exist along a spectrum of differentiated states 92, 93 . It will be important to discern how these prospective malignant populations align with their healthy counterparts as it may give insights into how specific lineages arrive at their malignant destinations in GBM. For example, one tantalizing possibility is that each of these unique astrocyte subpopulations is endowed with differential de-differentiation capacity or responses to specific oncogenic stimuli. This scenario would suggest a combinatorial code of genetic mutation and glial cellular context that explains, in part, the prospective origins of different forms of glioma.
At the molecular level, because GFAP is also highly expressed in glioma, its regulatory mechanisms contribute to tumorigenesis. Among these mechanisms, STAT3 is a key regulator of GFAP expression that plays key roles in oncogenesis in other systems. In glioma, a myriad of studies in human-derived glioma cell line and GSC systems have shown that STAT3 functions to promote glioma tumorigenesis 94 . Because STAT3 serves as a key signalling node for numerous pathways, it interfaces with several systems associated with glioma. Studies in mouse models have shown that loss of STAT3 in astrocytes suppresses growth; however, when combined with loss of PTEN, STAT3 function becomes oncogenic 95 . Thus, much like NOTCH-RBPJ, STAT3 function is also context-dependent. STAT3 has also been linked to EGFR signalling, in which EGFR can activate STAT3 and it complexes with mutant, activated forms of EGFR variant III to drive tumorigenesis 96 . This relationship is part of a feedforward mechanism whereby STAT3 regulates both inducible nitric oxide synthase (iNOS; also known as NOS2) and oncostatin-M-specific receptor subunit-β (OSMR) expression, which subsequently complex with EGFR and facilitates the EGFR-STAT3 interaction and tumorigenesis 97 . Given its ubiquity across malignancies, considerable efforts have been made to develop therapeutics that target STAT3. Current approaches involve targeting the upstream regulators Janus kinase 1 (JAK1)-JAK2 or activated STAT3 itself 98, 99 . In both cases, the broad roles of these factors in numerous core cellular processes limit their efficacy; moreover, current STAT3 inhibitors may have off-target effects. These limitations, coupled with the central role of STAT3 in glioma, illustrate the need to develop new therapeutics for this pathway.
Blazing a gliogenic path
The rationale for studying developmental gliogenesis in the context of glioma is the hope that understanding how to make glial cells will inform how glioma is generated and will reveal new approaches for curbing glioma growth. By viewing the problem of glial malignancy from the developmental perspective, the concept of differentiation therapy emerges, in which the manipulation of defined developmental factors influences the production of tumour cells. This paradigm has been exploited for haematopoietic malignancies, in which treatment of acute promyelocytic leukaemia with retinoic acid and arsenic results in differentiation of malignant progenitors and disease remission 100 . Although promising, these implementing parallel approaches in solid tumours have proved challenging. For glioma, the first steps of this journey will be identifying pathways that influence tumour subtype differentiation in native and human cell line models. Indeed, studies with the glial transcription factors NFIA and Olig2 in native mouse models of glioma have shown that manipulating these factors can influence the type of glioma generated (Fig. 3) . These observations highlight the need to more carefully examine how glial development factors influence molecular and cellular identities in native models of glioma as targeting these pathways may direct a form of differentiation therapy.
In the era of genomics, we are on the verge of cataloguing every mutation present in glioma. Although this is an impressive feat, new therapeutics for this malicious disease will result only from acting on this information.
Viewing these questions through the lens of glial development, two critical areas of investigation emerge. First is decoding the cellular correlates of genetic mutation by understanding how specific glial cellular contexts interface with key genetic drivers of glioma. This decoding will require identifying the various heterogeneous cell populations that comprise the healthy brain and primary glioma tumours and deciphering how genetic drivers of this disease create malignant populations from normal glial substrates. Deconvolution of this potentially immense cellular diversity begins with an understanding of normal glial diversity, both mature and immature populations, and identifying analogous populations in glioma models. Towards this, established methodologies harnessing single-cell approaches, in combination with direct functional screening of inferred cellular diversity, will be critical. Second is acquiring an understanding of the molecular interface between glial developmental factors and key drivers of tumorigenesis to influence cell fate and tumorigenesis. Given the potential interdependence between these factors during tumorigenesis (see earlier discussion of STAT3-PTEN), these relationships will likely guide how differentiation therapies are implemented. Moving forward, it will be critical to merge these vast genomic data sets with the developmental and cellular context in which they function.
